

RAW SEQUENCE LISTING

The Biotechnology Systems Branch of the Scientific and Technical
Information Center (STIC) no errors detected.

Application Serial Number: 10/517,600A
Source: 1 FWP
Date Processed by STIC: 10/19/06

ENTERED

CRF Errors Edited by the STIC Systems Branch

Serial Number: 10/517,600A

CRF Edit Date: 10/19/06
Edited by: JS

___ Realigned nucleic acid/amino acid numbers/text in cases where the sequence text "wrapped" to the next line

___ Corrected the SEQ ID NO. Sequence numbers edited were:

___ Inserted or corrected a nucleic number at the end of a nucleic line. SEQ ID NO's edited:

___ Deleted: ___ invalid beginning/end-of-file text ; ___ page numbers

___ Inserted mandatory headings/numeric identifiers, specifically:

___ Moved responses to same line as heading/numeric identifier, specifically:

✓ Other: Sequence 68-corrected the "Xaa" term



IFWP

RAW SEQUENCE LISTING

DATE: 10/19/2006

PATENT APPLICATION: US/10/517,600A

TIME: 15:52:10

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\10192006\J517600A.raw

```

3 <110> APPLICANT: Sugiyama, Haruo
4     Gotoh, Masashi
5     Takasu, Hideo
7 <120> TITLE OF INVENTION: HLA-A24-RESTRICTED CANCER ANTIGEN PEPTIDES
9 <130> FILE REFERENCE: 275596USXPCT
11 <140> CURRENT APPLICATION NUMBER: 10/517,600A
12 <141> CURRENT FILING DATE: 2004-12-13
14 <150> PRIOR APPLICATION NUMBER: PCT/JP03/07463
15 <151> PRIOR FILING DATE: 2003-06-12
17 <150> PRIOR APPLICATION NUMBER: JP 2002-171518
18 <151> PRIOR FILING DATE: 2002-06-12
20 <150> PRIOR APPLICATION NUMBER: JP 2002-275572
21 <151> PRIOR FILING DATE: 2002-09-20
23 <160> NUMBER OF SEQ ID NOS: 68
25 <170> SOFTWARE: PatentIn version 3.3
27 <210> SEQ ID NO: 1
28 <211> LENGTH: 449
29 <212> TYPE: PRT
30 <213> ORGANISM: Homo sapiens
32 <400> SEQUENCE: 1
34 Met Gly Ser Asp Val Arg Asp Leu Asn Ala Leu Leu Pro Ala Val Pro
35 1           5           10           15
38 Ser Leu Gly Gly Gly Gly Gly Cys Ala Leu Pro Val Ser Gly Ala Ala
39           20           25           30
42 Gln Trp Ala Pro Val Leu Asp Phe Ala Pro Pro Gly Ala Ser Ala Tyr
43           35           40           45
46 Gly Ser Leu Gly Gly Pro Ala Pro Pro Pro Ala Pro Pro Pro Pro
47           50           55           60
50 Pro Pro Pro Pro His Ser Phe Ile Lys Gln Glu Pro Ser Trp Gly Gly
51 65           70           75           80
54 Ala Glu Pro His Glu Glu Gln Cys Leu Ser Ala Phe Thr Val His Phe
55           85           90           95
58 Ser Gly Gln Phe Thr Gly Thr Ala Gly Ala Cys Arg Tyr Gly Pro Phe
59           100          105          110
62 Gly Pro Pro Pro Pro Ser Gln Ala Ser Ser Gly Gln Ala Arg Met Phe
63           115          120          125
66 Pro Asn Ala Pro Tyr Leu Pro Ser Cys Leu Glu Ser Gln Pro Ala Ile
67           130          135          140
70 Arg Asn Gln Gly Tyr Ser Thr Val Thr Phe Asp Gly Thr Pro Ser Tyr
71 145          150          155          160
74 Gly His Thr Pro Ser His His Ala Ala Gln Phe Pro Asn His Ser Phe
75           165          170          175
78 Lys His Glu Asp Pro Met Gly Gln Gln Gly Ser Leu Gly Glu Gln Gln

```

RAW SEQUENCE LISTING

DATE: 10/19/2006

PATENT APPLICATION: US/10/517,600A

TIME: 15:52:10

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\10192006\J517600A.raw

```

79          180          185          190
82 Tyr Ser Val Pro Pro Pro Val Tyr Gly Cys His Thr Pro Thr Asp Ser
83          195          200          205
86 Cys Thr Gly Ser Gln Ala Leu Leu Arg Thr Pro Tyr Ser Ser Asp
87          210          215          220
90 Asn Leu Tyr Gln Met Thr Ser Gln Leu Glu Cys Met Thr Trp Asn Gln
91 225          230          235          240
94 Met Asn Leu Gly Ala Thr Leu Lys Gly Val Ala Ala Gly Ser Ser Ser
95          245          250          255
98 Ser Val Lys Trp Thr Glu Gly Gln Ser Asn His Ser Thr Gly Tyr Glu
99          260          265          270
102 Ser Asp Asn His Thr Thr Pro Ile Leu Cys Gly Ala Gln Tyr Arg Ile
103          275          280          285
106 His Thr His Gly Val Phe Arg Gly Ile Gln Asp Val Arg Arg Val Pro
107          290          295          300
110 Gly Val Ala Pro Thr Leu Val Arg Ser Ala Ser Glu Thr Ser Glu Lys
111 305          310          315          320
114 Arg Pro Phe Met Cys Ala Tyr Pro Gly Cys Asn Lys Arg Tyr Phe Lys
115          325          330          335
118 Leu Ser His Leu Gln Met His Ser Arg Lys His Thr Gly Glu Lys Pro
119          340          345          350
122 Tyr Gln Cys Asp Phe Lys Asp Cys Glu Arg Arg Phe Ser Arg Ser Asp
123          355          360          365
126 Gln Leu Lys Arg His Gln Arg Arg His Thr Gly Val Lys Pro Phe Gln
127          370          375          380
130 Cys Lys Thr Cys Gln Arg Lys Phe Ser Arg Ser Asp His Leu Lys Thr
131 385          390          395          400
134 His Thr Arg Thr His Thr Gly Lys Thr Ser Glu Lys Pro Phe Ser Cys
135          405          410          415
138 Arg Trp Pro Ser Cys Gln Lys Lys Phe Ala Arg Ser Asp Glu Leu Val
139          420          425          430
142 Arg His His Asn Met His Gln Arg Asn Met Thr Lys Leu Gln Leu Ala
143          435          440          445
146 Leu
150 <210> SEQ ID NO: 2
151 <211> LENGTH: 9
152 <212> TYPE: PRT
153 <213> ORGANISM: Artificial Sequence
155 <220> FEATURE:
156 <223> OTHER INFORMATION: Synthetic Peptide
158 <400> SEQUENCE: 2
160 Arg Tyr Phe Pro Asn Ala Pro Tyr Leu
161 1          5
164 <210> SEQ ID NO: 3
165 <211> LENGTH: 9
166 <212> TYPE: PRT
167 <213> ORGANISM: Artificial Sequence
169 <220> FEATURE:
170 <223> OTHER INFORMATION: Synthetic Peptide

```

RAW SEQUENCE LISTING

DATE: 10/19/2006

PATENT APPLICATION: US/10/517,600A

TIME: 15:52:10

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\10192006\J517600A.raw

172 <400> SEQUENCE: 3
174 Arg Tyr Pro Gly Val Ala Pro Thr Leu
175 1 5
178 <210> SEQ ID NO: 4
179 <211> LENGTH: 9
180 <212> TYPE: PRT
181 <213> ORGANISM: Artificial Sequence
183 <220> FEATURE:
184 <223> OTHER INFORMATION: Synthetic Peptide
186 <400> SEQUENCE: 4
188 Arg Tyr Pro Ser Cys Gln Lys Lys Phe
189 1 5
192 <210> SEQ ID NO: 5
193 <211> LENGTH: 9
194 <212> TYPE: PRT
195 <213> ORGANISM: Artificial Sequence
197 <220> FEATURE:
198 <223> OTHER INFORMATION: Synthetic Peptide
200 <400> SEQUENCE: 5
202 Ala Tyr Leu Pro Ala Val Pro Ser Leu
203 1 5
206 <210> SEQ ID NO: 6
207 <211> LENGTH: 9
208 <212> TYPE: PRT
209 <213> ORGANISM: Artificial Sequence
211 <220> FEATURE:
212 <223> OTHER INFORMATION: Synthetic Peptide
214 <400> SEQUENCE: 6
216 Asn Tyr Met Asn Leu Gly Ala Thr Leu
217 1 5
220 <210> SEQ ID NO: 7
221 <211> LENGTH: 9
222 <212> TYPE: PRT
223 <213> ORGANISM: Artificial Sequence
225 <220> FEATURE:
226 <223> OTHER INFORMATION: Synthetic Peptide
228 <400> SEQUENCE: 7
230 Arg Val Pro Gly Val Ala Pro Thr Leu
231 1 5
234 <210> SEQ ID NO: 8
235 <211> LENGTH: 9
236 <212> TYPE: PRT
237 <213> ORGANISM: Artificial Sequence
239 <220> FEATURE:
240 <223> OTHER INFORMATION: Synthetic Peptide
242 <400> SEQUENCE: 8
244 Arg Met Phe Pro Asn Ala Pro Tyr Leu
245 1 5
248 <210> SEQ ID NO: 9

RAW SEQUENCE LISTING

DATE: 10/19/2006

PATENT APPLICATION: US/10/517,600A

TIME: 15:52:10

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\10192006\J517600A.raw

249 <211> LENGTH: 9
250 <212> TYPE: PRT
251 <213> ORGANISM: Artificial Sequence
253 <220> FEATURE:
254 <223> OTHER INFORMATION: Synthetic Peptide
256 <400> SEQUENCE: 9
258 Arg Trp Pro Ser Cys Gln Lys Lys Phe
259 1 5
262 <210> SEQ ID NO: 10
263 <211> LENGTH: 10
264 <212> TYPE: PRT
265 <213> ORGANISM: Artificial Sequence
267 <220> FEATURE:
268 <223> OTHER INFORMATION: Synthetic Peptide
270 <400> SEQUENCE: 10
272 Gln Tyr Arg Ile His Thr His Gly Val Phe
273 1 5 10
276 <210> SEQ ID NO: 11
277 <211> LENGTH: 10
278 <212> TYPE: PRT
279 <213> ORGANISM: Artificial Sequence
281 <220> FEATURE:
282 <223> OTHER INFORMATION: Synthetic Peptide
284 <400> SEQUENCE: 11
286 Ala Tyr Pro Gly Cys Asn Lys Arg Tyr Phe
287 1 5 10
290 <210> SEQ ID NO: 12
291 <211> LENGTH: 9
292 <212> TYPE: PRT
293 <213> ORGANISM: Artificial Sequence
295 <220> FEATURE:
296 <223> OTHER INFORMATION: Synthetic Peptide
298 <400> SEQUENCE: 12
300 Arg Tyr Phe Pro Asn Ala Pro Tyr Phe
301 1 5
304 <210> SEQ ID NO: 13
305 <211> LENGTH: 9
306 <212> TYPE: PRT
307 <213> ORGANISM: Artificial Sequence
309 <220> FEATURE:
310 <223> OTHER INFORMATION: Synthetic Peptide
312 <400> SEQUENCE: 13
314 Arg Tyr Phe Pro Asn Ala Pro Tyr Trp
315 1 5
318 <210> SEQ ID NO: 14
319 <211> LENGTH: 9
320 <212> TYPE: PRT
321 <213> ORGANISM: Artificial Sequence
323 <220> FEATURE:

RAW SEQUENCE LISTING

DATE: 10/19/2006

PATENT APPLICATION: US/10/517,600A

TIME: 15:52:10

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\10192006\J517600A.raw

324 <223> OTHER INFORMATION: Synthetic Peptide
326 <400> SEQUENCE: 14
328 Arg Tyr Phe Pro Asn Ala Pro Tyr Ile
329 1 5
332 <210> SEQ ID NO: 15
333 <211> LENGTH: 9
334 <212> TYPE: PRT
335 <213> ORGANISM: Artificial Sequence
337 <220> FEATURE:
338 <223> OTHER INFORMATION: Synthetic Peptide
340 <400> SEQUENCE: 15
342 Arg Tyr Phe Pro Asn Ala Pro Tyr Met
343 1 5
346 <210> SEQ ID NO: 16
347 <211> LENGTH: 9
348 <212> TYPE: PRT
349 <213> ORGANISM: Artificial Sequence
351 <220> FEATURE:
352 <223> OTHER INFORMATION: Synthetic Peptide
354 <400> SEQUENCE: 16
356 Arg Tyr Pro Gly Val Ala Pro Thr Phe
357 1 5
360 <210> SEQ ID NO: 17
361 <211> LENGTH: 9
362 <212> TYPE: PRT
363 <213> ORGANISM: Artificial Sequence
365 <220> FEATURE:
366 <223> OTHER INFORMATION: Synthetic Peptide
368 <400> SEQUENCE: 17
370 Arg Tyr Pro Gly Val Ala Pro Thr Trp
371 1 5
374 <210> SEQ ID NO: 18
375 <211> LENGTH: 9
376 <212> TYPE: PRT
377 <213> ORGANISM: Artificial Sequence
379 <220> FEATURE:
380 <223> OTHER INFORMATION: Synthetic Peptide
382 <400> SEQUENCE: 18
384 Arg Tyr Pro Gly Val Ala Pro Thr Ile
385 1 5
388 <210> SEQ ID NO: 19
389 <211> LENGTH: 9
390 <212> TYPE: PRT
391 <213> ORGANISM: Artificial Sequence
393 <220> FEATURE:
394 <223> OTHER INFORMATION: Synthetic Peptide
396 <400> SEQUENCE: 19
398 Arg Tyr Pro Gly Val Ala Pro Thr Met
399 1 5

RAW SEQUENCE LISTING ERROR SUMMARY DATE: 10/19/2006
PATENT APPLICATION: US/10/517,600A TIME: 15:52:11

Input Set : A:\PTO.AMC.txt
Output Set: N:\CRF4\10192006\J517600A.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:68; Xaa Pos. 5

VERIFICATION SUMMARY

DATE: 10/19/2006

PATENT APPLICATION: US/10/517,600A

TIME: 15:52:11

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\10192006\J517600A.raw

L:1326 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:68 after pos.:0

**Raw Sequence Listing before editing
(for reference only)**



IFWP

RAW SEQUENCE LISTING

DATE: 10/18/2006

PATENT APPLICATION: US/10/517,600A

TIME: 10:21:59

Input Set : A:\275596USXPCT.ST25.txt

Output Set: N:\CRF4\10182006\J517600A.raw

3 <110> APPLICANT: Sugiyama, Haruo
 4 Gotoh, Masashi
 5 Takasu, Hideo
 7 <120> TITLE OF INVENTION: HLA-A24-RESTRICTED CANCER ANTIGEN PEPTIDES
 9 <130> FILE REFERENCE: 275596USXPCT
 11 <140> CURRENT APPLICATION NUMBER: 10/517,600A
 12 <141> CURRENT FILING DATE: 2004-12-13
 14 <150> PRIOR APPLICATION NUMBER: PCT/JP03/07463
 15 <151> PRIOR FILING DATE: 2003-06-12
 17 <150> PRIOR APPLICATION NUMBER: JP 2002-171518
 18 <151> PRIOR FILING DATE: 2002-06-12
 20 <150> PRIOR APPLICATION NUMBER: JP 2002-275572
 21 <151> PRIOR FILING DATE: 2002-09-20
 23 <160> NUMBER OF SEQ ID NOS: 68
 25 <170> SOFTWARE: PatentIn version 3.3
 27 <210> SEQ ID NO: 1
 28 <211> LENGTH: 449
 29 <212> TYPE: PRT
 30 <213> ORGANISM: Homo sapiens
 32 <400> SEQUENCE: 1
 34 Met Gly Ser Asp Val Arg Asp Leu Asn Ala Leu Leu Pro Ala Val Pro
 35 1 5 10 15
 38 Ser Leu Gly Gly Gly Gly Gly Cys Ala Leu Pro Val Ser Gly Ala Ala
 39 20 25 30
 42 Gln Trp Ala Pro Val Leu Asp Phe Ala Pro Pro Gly Ala Ser Ala Tyr
 43 35 40 45
 46 Gly Ser Leu Gly Gly Pro Ala Pro Pro Pro Ala Pro Pro Pro Pro
 47 50 55 60
 50 Pro Pro Pro Pro His Ser Phe Ile Lys Gln Glu Pro Ser Trp Gly Gly
 51 65 70 75 80
 54 Ala Glu Pro His Glu Gln Cys Leu Ser Ala Phe Thr Val His Phe
 55 85 90 95
 58 Ser Gly Gln Phe Thr Gly Thr Ala Gly Ala Cys Arg Tyr Gly Pro Phe
 59 100 105 110
 62 Gly Pro Pro Pro Pro Ser Gln Ala Ser Ser Gly Gln Ala Arg Met Phe
 63 115 120 125
 66 Pro Asn Ala Pro Tyr Leu Pro Ser Cys Leu Glu Ser Gln Pro Ala Ile
 67 130 135 140
 70 Arg Asn Gln Gly Tyr Ser Thr Val Thr Phe Asp Gly Thr Pro Ser Tyr
 71 145 150 155 160
 74 Gly His Thr Pro Ser His His Ala Ala Gln Phe Pro Asn His Ser Phe
 75 165 170 175
 78 Lys His Glu Asp Pro Met Gly Gln Gln Gly Ser Leu Gly Glu Gln Gln

Does Not Comply
Corrected Diskette Needed

see p. 8

RAW SEQUENCE LISTING

DATE: 10/18/2006

PATENT APPLICATION: US/10/517,600A

TIME: 10:21:59

Input Set : A:\275596USXPCT.ST25.txt

Output Set: N:\CRF4\10182006\J517600A.raw

```

79          180          185          190
82 Tyr Ser Val Pro Pro Pro Val Tyr Gly Cys His Thr Pro Thr Asp Ser
83          195          200          205
86 Cys Thr Gly Ser Gln Ala Leu Leu Arg Thr Pro Tyr Ser Ser Asp
87          210          215          220
90 Asn Leu Tyr Gln Met Thr Ser Gln Leu Glu Cys Met Thr Trp Asn Gln
91 225          230          235          240
94 Met Asn Leu Gly Ala Thr Leu Lys Gly Val Ala Ala Gly Ser Ser Ser
95          245          250          255
98 Ser Val Lys Trp Thr Glu Gly Gln Ser Asn His Ser Thr Gly Tyr Glu
99          260          265          270
102 Ser Asp Asn His Thr Thr Pro Ile Leu Cys Gly Ala Gln Tyr Arg Ile
103          275          280          285
106 His Thr His Gly Val Phe Arg Gly Ile Gln Asp Val Arg Arg Val Pro
107          290          295          300
110 Gly Val Ala Pro Thr Leu Val Arg Ser Ala Ser Glu Thr Ser Glu Lys
111 305          310          315          320
114 Arg Pro Phe Met Cys Ala Tyr Pro Gly Cys Asn Lys Arg Tyr Phe Lys
115          325          330          335
118 Leu Ser His Leu Gln Met His Ser Arg Lys His Thr Gly Glu Lys Pro
119          340          345          350
122 Tyr Gln Cys Asp Phe Lys Asp Cys Glu Arg Arg Phe Ser Arg Ser Asp
123          355          360          365
126 Gln Leu Lys Arg His Gln Arg Arg His Thr Gly Val Lys Pro Phe Gln
127          370          375          380
130 Cys Lys Thr Cys Gln Arg Lys Phe Ser Arg Ser Asp His Leu Lys Thr
131 385          390          395          400
134 His Thr Arg Thr His Thr Gly Lys Thr Ser Glu Lys Pro Phe Ser Cys
135          405          410          415
138 Arg Trp Pro Ser Cys Gln Lys Lys Phe Ala Arg Ser Asp Glu Leu Val
139          420          425          430
142 Arg His His Asn Met His Gln Arg Asn Met Thr Lys Leu Gln Leu Ala
143          435          440          445
146 Leu

```

150 <210> SEQ ID NO: 2

151 <211> LENGTH: 9

152 <212> TYPE: PRT

153 <213> ORGANISM: Artificial Sequence

155 <220> FEATURE:

156 <223> OTHER INFORMATION: Synthetic Peptide

158 <400> SEQUENCE: 2

160 Arg Tyr Phe Pro Asn Ala Pro Tyr Leu

161 1 5

164 <210> SEQ ID NO: 3

165 <211> LENGTH: 9

166 <212> TYPE: PRT

167 <213> ORGANISM: Artificial Sequence

169 <220> FEATURE:

170 <223> OTHER INFORMATION: Synthetic Peptide

RAW SEQUENCE LISTING

DATE: 10/18/2006

PATENT APPLICATION: US/10/517,600A

TIME: 10:21:59

Input Set : A:\275596USXPCT.ST25.txt

Output Set: N:\CRF4\10182006\J517600A.raw

172 <400> SEQUENCE: 3
174 Arg Tyr Pro Gly Val Ala Pro Thr Leu
175 1 5
178 <210> SEQ ID NO: 4
179 <211> LENGTH: 9
180 <212> TYPE: PRT
181 <213> ORGANISM: Artificial Sequence
183 <220> FEATURE:
184 <223> OTHER INFORMATION: Synthetic Peptide
186 <400> SEQUENCE: 4
188 Arg Tyr Pro Ser Cys Gln Lys Lys Phe
189 1 5
192 <210> SEQ ID NO: 5
193 <211> LENGTH: 9
194 <212> TYPE: PRT
195 <213> ORGANISM: Artificial Sequence
197 <220> FEATURE:
198 <223> OTHER INFORMATION: Synthetic Peptide
200 <400> SEQUENCE: 5
202 Ala Tyr Leu Pro Ala Val Pro Ser Leu
203 1 5
206 <210> SEQ ID NO: 6
207 <211> LENGTH: 9
208 <212> TYPE: PRT
209 <213> ORGANISM: Artificial Sequence
211 <220> FEATURE:
212 <223> OTHER INFORMATION: Synthetic Peptide
214 <400> SEQUENCE: 6
216 Asn Tyr Met Asn Leu Gly Ala Thr Leu
217 1 5
220 <210> SEQ ID NO: 7
221 <211> LENGTH: 9
222 <212> TYPE: PRT
223 <213> ORGANISM: Artificial Sequence
225 <220> FEATURE:
226 <223> OTHER INFORMATION: Synthetic Peptide
228 <400> SEQUENCE: 7
230 Arg Val Pro Gly Val Ala Pro Thr Leu
231 1 5
234 <210> SEQ ID NO: 8
235 <211> LENGTH: 9
236 <212> TYPE: PRT
237 <213> ORGANISM: Artificial Sequence
239 <220> FEATURE:
240 <223> OTHER INFORMATION: Synthetic Peptide
242 <400> SEQUENCE: 8
244 Arg Met Phe Pro Asn Ala Pro Tyr Leu
245 1 5
248 <210> SEQ ID NO: 9

RAW SEQUENCE LISTING

DATE: 10/18/2006

PATENT APPLICATION: US/10/517,600A

TIME: 10:21:59

Input Set : A:\275596USXPCT.ST25.txt

Output Set: N:\CRF4\10182006\J517600A.raw

249 <211> LENGTH: 9
250 <212> TYPE: PRT
251 <213> ORGANISM: Artificial Sequence
253 <220> FEATURE:
254 <223> OTHER INFORMATION: Synthetic Peptide
256 <400> SEQUENCE: 9
258 Arg Trp Pro Ser Cys Gln Lys Lys Phe
259 1 5
262 <210> SEQ ID NO: 10
263 <211> LENGTH: 10
264 <212> TYPE: PRT
265 <213> ORGANISM: Artificial Sequence
267 <220> FEATURE:
268 <223> OTHER INFORMATION: Synthetic Peptide
270 <400> SEQUENCE: 10
272 Gln Tyr Arg Ile His Thr His Gly Val Phe
273 1 5 10
276 <210> SEQ ID NO: 11
277 <211> LENGTH: 10
278 <212> TYPE: PRT
279 <213> ORGANISM: Artificial Sequence
281 <220> FEATURE:
282 <223> OTHER INFORMATION: Synthetic Peptide
284 <400> SEQUENCE: 11
286 Ala Tyr Pro Gly Cys Asn Lys Arg Tyr Phe
287 1 5 10
290 <210> SEQ ID NO: 12
291 <211> LENGTH: 9
292 <212> TYPE: PRT
293 <213> ORGANISM: Artificial Sequence
295 <220> FEATURE:
296 <223> OTHER INFORMATION: Synthetic Peptide
298 <400> SEQUENCE: 12
300 Arg Tyr Phe Pro Asn Ala Pro Tyr Phe
301 1 5
304 <210> SEQ ID NO: 13
305 <211> LENGTH: 9
306 <212> TYPE: PRT
307 <213> ORGANISM: Artificial Sequence
309 <220> FEATURE:
310 <223> OTHER INFORMATION: Synthetic Peptide
312 <400> SEQUENCE: 13
314 Arg Tyr Phe Pro Asn Ala Pro Tyr Trp
315 1 5
318 <210> SEQ ID NO: 14
319 <211> LENGTH: 9
320 <212> TYPE: PRT
321 <213> ORGANISM: Artificial Sequence
323 <220> FEATURE:

RAW SEQUENCE LISTING

DATE: 10/18/2006

PATENT APPLICATION: US/10/517,600A

TIME: 10:21:59

Input Set : A:\275596USXPCT.ST25.txt

Output Set: N:\CRF4\10182006\J517600A.raw

324 <223> OTHER INFORMATION: Synthetic Peptide
326 <400> SEQUENCE: 14
328 Arg Tyr Phe Pro Asn Ala Pro Tyr Ile
329 1 5
332 <210> SEQ ID NO: 15
333 <211> LENGTH: 9
334 <212> TYPE: PRT
335 <213> ORGANISM: Artificial Sequence
337 <220> FEATURE:
338 <223> OTHER INFORMATION: Synthetic Peptide
340 <400> SEQUENCE: 15
342 Arg Tyr Phe Pro Asn Ala Pro Tyr Met
343 1 5
346 <210> SEQ ID NO: 16
347 <211> LENGTH: 9
348 <212> TYPE: PRT
349 <213> ORGANISM: Artificial Sequence
351 <220> FEATURE:
352 <223> OTHER INFORMATION: Synthetic Peptide
354 <400> SEQUENCE: 16
356 Arg Tyr Pro Gly Val Ala Pro Thr Phe
357 1 5
360 <210> SEQ ID NO: 17
361 <211> LENGTH: 9
362 <212> TYPE: PRT
363 <213> ORGANISM: Artificial Sequence
365 <220> FEATURE:
366 <223> OTHER INFORMATION: Synthetic Peptide
368 <400> SEQUENCE: 17
370 Arg Tyr Pro Gly Val Ala Pro Thr Trp
371 1 5
374 <210> SEQ ID NO: 18
375 <211> LENGTH: 9
376 <212> TYPE: PRT
377 <213> ORGANISM: Artificial Sequence
379 <220> FEATURE:
380 <223> OTHER INFORMATION: Synthetic Peptide
382 <400> SEQUENCE: 18
384 Arg Tyr Pro Gly Val Ala Pro Thr Ile
385 1 5
388 <210> SEQ ID NO: 19
389 <211> LENGTH: 9
390 <212> TYPE: PRT
391 <213> ORGANISM: Artificial Sequence
393 <220> FEATURE:
394 <223> OTHER INFORMATION: Synthetic Peptide
396 <400> SEQUENCE: 19
398 Arg Tyr Pro Gly Val Ala Pro Thr Met
399 1 5

RAW SEQUENCE LISTING ERROR SUMMARY DATE: 10/18/2006
PATENT APPLICATION: US/10/517,600A TIME: 10:22:00

Input Set : A:\275596USXPCT.ST25.txt
Output Set: N:\CRF4\10182006\J517600A.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:68; Xaa Pos. 5

VERIFICATION SUMMARY

DATE: 10/18/2006

PATENT APPLICATION: US/10/517,600A

TIME: 10:22:00

Input Set : A:\275596USXPCT.ST25.txt

Output Set: N:\CRF4\10182006\J517600A.raw

L:1326 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:68 after pos.:0

10/517,600A

8

<210> 68
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Peptide

<220>
<221> MISC_FEATURE

<222> (5)..(5)

<223> Axx = Abu

<400> 68 Xaa

Arg Tyr Pro Ser Xaa Gln Lys Lys Phe
1 5